Rituximab (Anti-CD20 Monoclonal Antibody) Administration in a Young Patient with Resistant B-Prolymphocytic Leukemia

Publisher： Karger

E-ISSN： 1421-9662|102|2|94-98

ISSN： 0001-5792

Source： Acta Haematologica, Vol.102, Iss.2, 1999-10, pp. : 94-98

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group

By  

Case Reports in Oncology, Vol. 2, Iss. 3, 2009-10 ,pp. : 194-202

Karger

Access to resources Recommend Favorite

Effective Treatment of Refractory Pulmonary Hemorrhage with Monoclonal Anti-CD20 Antibody (Rituximab)

By  

Respiration, Vol. 78, Iss. 1, 2008-09 ,pp. : 106-109

Karger

Access to resources Recommend Favorite

Anti-CD20 Monoclonal Antibody (Rituximab) and Cidofovir as Successful Treatment of an EBV-Associated Lymphoma with CNS Involvement

By  

Oncology Research and Treatment, Vol. 24, Iss. 5, 2001-10 ,pp. : 491-494

Karger

Access to resources Recommend Favorite

Successful Treatment of EBV PTLD with CNS Lymphomas with the Monoclonal Anti-CD20 Antibody Rituximab

By  

Oncology Research and Treatment, Vol. 31, Iss. 12, 2008-11 ,pp. : 691-693

Karger

Access to resources Recommend Favorite

Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies

By Dillman R.  

Clinical and Experimental Medicine, Vol. 6, Iss. 1, 2006-03 ,pp. : 1-12

Springer Publishing Company

Access to resources Recommend Favorite